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Abstract
Data on the effectiveness of second-line combination antiretroviral therapy (cART) are limited. We evaluated
virologic outcomes of second cART in a multicenter cohort collaboration. The study population initiated first and
second modern cART between 1996 and 2010. The second cART required a switch in at least the anchor agent of
first cART. We evaluated time to virologic failure of second cART and factors associated with greater risk of
failure using multivariable Cox proportional hazards models. Of 488 patients who switched to second-line
cART, 67% were black and 32% were women. The median HIV-1 RNA at second cART initiation was 9,565
copies/ml [interquartile range (IQR); 123, 94,108]. The time to virologic failure of second cART was longer if
HIV-1 RNA was undetectable at switch ( p = 0.001), although 12% and 17% of patients with undetectable and
detectable HIV-1 RNA experienced virologic failure within 6 months of second cART initiation, respectively. A
lower CD4 cell count at second cART initiation was associated with a greater risk of virologic failure. Failure
rates decreased in more recent calendar years [adjusted relative hazard of 0.40 comparing 2008 to 2010 with 1996
to 1998 (95% confidence interval; 0.15, 1.00)]; however, type of anchor agent was not associated with failure. In
conclusion, virologic failure of second cART was less likely if patients switched with undetectable HIV-1 RNA,
although risk of early failure was similar. The effectiveness of second cART regimens improved over calendar
time and was independent of the anchor agent in the regimen.
Introduction
The potent efficacy of currently recommended combi-nation antiretroviral therapy (cART) regimens for ART-
naive patients in suppressing HIV RNA levels has been
clearly demonstrated in randomized clinical trials.1–4 Effec-
tive initial regimens with two nucleoside reverse transcriptase
inhibitors (NRTIs) and an anchor agent are well established,5,6
and preferred agents have good toxicity profiles and most
have a high barrier to resistance evolution.7–9 However, the
durability of first cART is limited by factors as varied as
preexisting resistance, toxicity, and/or intolerance, adher-
ence, and virologic failure.10,11
In clinical care in North America over 20% and 50% of
patients are no longer on their first cART by 6 and 24 months
following initiation, respectively.12 Although first cART reg-
imens have been simplified in recent calendar years, sub-
stantial heterogeneity and complexity remain in antiretroviral
combinations provided for second cART.13 Moreover, little
research exists on the management and outcomes of second
cART, and adequately powered randomized comparative
trials of second-line therapy, particularly in resource-rich
settings, are not available.14,15
Achieving virologic suppression on second cART may be
challenging as a switch to second-line therapy, whether mo-
tivated by virologic rebound, intolerability, or toxicity, is
frequently complicated by difficulty with adherence and may
involve more complex regimens.6 The long-term prognosis of
individuals with virologic failure on second cART has not
been well studied, but these individuals are likely to be at
higher risk of HIV-related morbidity and mortality in part due
to ongoing viral replication and further accumulation of HIV-1
resistance to antiretroviral agents.16 Therefore, in the present
multicenter cohort collaboration we evaluated virologic
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outcomes of second cART in clinical care, including time to
failure and patient demographic and clinical factors associated
with greater risk of failure.
Materials and Methods
Study population
The study population included patients enrolled in one of
three large U.S. clinical cohort studies, including the Van-
derbilt-Meharry Center for AIDS Research (CFAR) Cohort,
the Johns Hopkins HIV Clinical Cohort, and the UNC CFAR
HIV Clinical Cohort, all described previously, which com-
bined include over 15,000 HIV-infected individuals.17–19 In
brief, these observational studies follow rigorous and stan-
dardized data collection methods, including electronic data
capture from institutional records and periodic medical re-
cord reviews containing demographic, clinical, laboratory,
and medication data. Institutional review board approval was
obtained at each of the participating institutions.
For this study we included all patients who were receiving
HIV care at one of the three clinical sites and who were at least
18 years old. Patients must have initiated a first cART fol-
lowed by a second cART regimen. We excluded all patients
who initiated first cART prior to June 1996 (i.e., prior to the
introduction of cART) and patients without at least 8 weeks of
follow-up on their second cART.
Measures
A first and second cART regimen was defined as two or
more NRTIs with an anchor agent [i.e., a nonnucleoside re-
verse transcriptase inhibitor (NNRTI), a protease inhibitor
(PI), a ritonavir-boosted PI (PI/r), or an integrase strand-
transfer inhibitor (INSTI)]. To be considered as switching
from first to second cART required a switch in the anchor
agent (e.g., PI to NNRTI, NNRTI to PI, PI or NNRTI to INSTI),
irrespective of changes in the NRTI backbone. Neither the
addition of ritonavir to a PI nor a switch in any or all NRTIs
alone was considered as a switch from first to second cART.
Because the sensitivity of HIV-1 RNA testing assays in-
creased during the time frame of the study, an HIV-1 RNA
level < 400 copies/ml was considered successful virologic
suppression. For first cART, virologic failure was defined as
not reaching a decrease in an HIV-1 RNA level of at least 0.5
log10 copies/ml from cART initiation to 24 weeks or an HIV-1
RNA level of > 400 copies/ml after 24 weeks. The definition of
virologic failure for second cART was conditional on the HIV-
1 RNA level at the start of the second cART regimen. In pa-
tients with an HIV-1 RNA level > 400 copies/ml, virologic
failure was defined as a failure to achieve a decrease in the
HIV-1 RNA level of at least 0.5 log10 HIV-1 RNA by 24 weeks
or an HIV-1 RNA level of > 400 copies/ml after 24 weeks. For
patients with an HIV-1 RNA of < 400 copies/ml, virologic
failure was defined as an HIV-1 RNA > 400 copies/ml 8 weeks
after switch.
Statistical analysis
Patients were followed from first cART initiation until the first
of either their last reported HIV-1 RNA level while receiving
second cART, or June 2010. Basic bivariable contrasts included
performing the Pearson’s Chi-square test for categorical vari-
ables and the Mann–Whitney rank sum test for continuous
variables. We used Kaplan–Meier analyses and the log-rank test
to assess time to virologic failure on second cART overall and
stratified by patient demographic and clinical characteristics.
Multivariable Cox proportional hazards regression models were
fit to estimate relative hazards and 95% confidence intervals
(95% CI) of time to second cART virologic failure. Analyses
included assessing bivariable associations first and then fitting
full and reduced models. We evaluated the proportional haz-
ards assumption and all models were adjusted for clinical site.
All tests for assessing statistical significance were two-sided with
an a of 0.05, and analyses were performed using SAS version 9.2
(SAS Institute Inc., Cary, NC). Sensitivity analyses were con-
ducted using HIV RNA limits of 200 and 50 copies/ml in those
patients who were tested with a more sensitive plasma HIV
RNA assay.
Results
The median age of the 488 patients meeting inclusion cri-
teria was 37 years [interquartile range (IQR); 31, 44], and 32%
were women, 67% black, and 25% white (Table 1). At first
cART initiation the median CD4 cell count was 135 cells/mm3
(IQR; 27, 302) and the HIV-1 RNA level was 83,875 copies/ml
(IQR; 22,218, 284,817). Almost one-half of patients initiated
cART with an NNRTI (49%), while the remainder initiated
cART with either a PI (34%) or PI/r (19%). No patient on
INSTI-based initial therapy met the criteria for inclusion in
this analysis.
Table 1. Demographic and Clinical Characteristics
of Patients at First Combination Antiretroviral
Therapy Initiation, Among Persons Who
Subsequently Initiated a Second Regimen
and Met the Study Inclusion Criteria
Characteristic N (%) or median (IQR)
Total 488














Prior ADI 165 (33.8%)
CD4 cell count, cells/mm3 135 (27–302)
HIV-1 RNA level, copies/ml 83,875 (22,218–284,817)
cART anchor agent
NNRTI 237 (48.6%)
PI (unboosted) 160 (33.8%)
PI/r 91 (18.7%)
IQR, interquartile range; MSM, men who have sex with men; IDU,
intravenous drug use; ADI, AIDS-defining clinical condition; cART,
combination antiretroviral therapy; NNRTI, nonnucleoside reverse
transcriptase inhibitor; PI, protease inhibitor; PI/r, ritonavir-boosted
protease inhibitor.
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Over one-third of patients switched from their first to second
cART regimen when their plasma HIV RNA was < 400 c/ml
(38%) and the overall median HIV-1 RNA level at start of
second cART was 9,565 log10 copies/ml (IQR; 123, 94,108).
The time from first to second cART initiation was on average
just over 1.5 years, but depended on whether the patient had
an HIV RNA < 400 c/ml when they started second cART.
Among patients with detectable HIV-1 RNA at second cART
initiation, the median time from first to second cART initiation
was 520 days (IQR; 205, 1158) compared to 670 days (IQR;
280, 1535) among patients with HIV-1 RNA < 400 c/ml at
switch (Fig. 1) ( p = 0.01). On average, the time between pa-
tients discontinuing their first cART and starting their second
cART was 3 months (median 96 days: IQR; 0, 567).
FIG. 1. Time from first to
second combination antiretro-
viral therapy initiation strati-
fied by HIV-1 RNA level at
time of antiretroviral switch,
multicohort collaboration 1996–
2010. Note: undetectable de-
fined as HIV-1 RNA < 400
copies/ml, detectable defined
as HIV-1 RNA ‡ 400 copies/ml.
Table 2. Clinical Characteristics of Patients at Start of Second Combination Antiretroviral Therapy
Stratified by HIV-1 RNA Level at Time of Antiretroviral Switch, Multicohort Collaboration 1996–2010
Characteristic All Undetectable Detectable
N 488 183 305
CD4 cell count, cells/mm3 247 (85–433) 433 (292–712) 175 (44–308)
£ 50 87 (17.8%) 6 (3.2%) 81 (26.6%)
51–200 113 (23.1%) 25 (13.7%) 88 (28.9%)
201–350 109 (22.3%) 33 (18.0%) 76 (24.9%)
351–500 84 (17.2%) 44 (24.0%) 40 (13.1%)
‡ 501 95 (19.5%) 75 (42.0%) 20 (21.1%)
HIV-1 RNA level, copies/ml 9,565 (123–94,108) 50 (50–128) 49,177 (11,094–160,653)
£ 400 183 (37.5%) 183 (100%) 0 (0.0%)
401–1,000 13 (2.7%) 13 (4.3%)
1,001–10,000 58 (11.9%) 58 (19.0%)
10,001–100,000 131 (26.9%) 131 (43.0%)
‡ 100,001 103 (21.1%) 103 (33.8%)
Second cART anchor agent
NNRTI in first cART
PI 228 (46.7%) 60 (32.8%) 168 (55.1%)
INSTI 8 (1.6%) 4 (2.2%) 4 (1.3%)
NNRTI (ETV) 2 (0.4%) 2 (1.1%) 0 (0.0%)
PI in first cART
NNRTI 207 (42.4%) 93 (50.8%) 114 (37.4%)
PI (DRV or TPV) 25 (5.1%) 10 (5.5%) 15 (4.9%)
INSTI 24 (4.9%) 17 (9.3%) 7 (2.3%)
Calendar year
1996–2003 214 (43.9%) 60 (32.8%) 154 (50.5%)
2004–2010 274 (56.2%) 123 (65.2%) 151 (49.5%)
Undetectable and detectable defined as HIV-1 RNA < and ‡ 400 copies/ml, respectively; IQR, interquartile range; cART, combination
antiretroviral therapy; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor; INSTI, integrase strand-transfer inhibitor;
ETV, etravirine; DRV, darunavir; TPV, tipranavir.
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At second cART initiation the median CD4 cell count was
247 cells/mm3 (IQR; 85, 433) (Table 2), on average approxi-
mately 100 cells/mm3 higher than at first cART initiation.
Over one-third of patients (37%) started their second cART
with a CD4 cell count > 350 cells/mm3. The most commonly
used anchor agent of second cART was a PI (51%), with the
vast majority ritonavir-boosted (*90%). Most switches were
either a modification from an NNRTI or PI to a PI (47%) or
from a PI to an NNRTI (42%). Sixty percent of second-line
treatment regimens in patients who switched with an HIV
RNA > 400 c/ml were PI based; use of INSTI-based regimens
were uncommon (4.6%). As newer antiretroviral agents be-
came available these were used in second cART, for example
10% (n = 26/274) of patients switching between 2004 and 2010
were switched from either a PI or NNRTI to a raltegravir-
based or etravirine-based regimen although most of these
patients had HIV RNA < 400 c/ml.
Time to virologic failure of second cART was significantly
different based on the HIV-1 RNA level at switch. Among
patients with a detectable HIV-1 RNA at second cART initi-
ation the median time to virologic failure was 605 days (IQR;
240, 2250), in comparison to > 1,500 days (IQR; 730, > 1500)
among patients with undetectable HIV-1 RNA ( p = 0.001)
(Fig. 2A). However, a similar proportion of patients had vi-
rologic failure early after switching, with 12% and 17% failing
virologically by 6 months after start of second cART among
patients undetectable and detectable at switch, respectively.
The time to virologic failure of second cART among patients
who initiated second cART with detectable HIV-1 RNA was
somewhat shorter (but not significantly) among persons
whose second cART anchor agent was a PI in comparison to
NNRTI, irrespective of whether the PI in the first cART regi-
men was ritonavir-boosted (Fig. 2B).
Using different cut-points for virologic suppression ( < 400,
< 200, and < 50 copies/ml) did not significantly alter the time to
virologic failure in patients who were below the limit at the time
of switch (Supplementary Fig. S1; Supplementary Data are
available online at www.liebertpub.com/aid). We had data
FIG. 2. Time to virologic
failure of second combination
antiretroviral therapy, multi-
cohort collaboration 1996–
2010: (A) among all patients
stratified by HIV-1 RNA level
at initiation (n = 488); (B)
among patients with detect-
able HIV-1 RNA at initiation
stratified by anchor agents
received (n = 277). Note: un-
detectable defined as HIV-1
RNA < 400 copies/ml, detect-
able defined as HIV-1 RNA ‡
400 copies/ml. NNRTI, non-
nucleoside reverse transcri-
ptase inhibitor; PI, protease
inhibitor; PI/r, ritonavir-
boosted PI.
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available on resistance testing for two of the three sites. At these
two sites of 270 patients who were virologically detectable at
switch 158 (59%) had an HIV genotype available after starting
their first cART and prior to starting their second cART. Among
those with a genotype 49% (77 of 158) subsequently experienced
virologic failure, and 47% (52 of 112) of those without a genotype
subsequently failed virologically ( p = 0.71).
In multivariable analyses of time to second cART virologic
failure, both higher CD4 cell count and more recent calendar
year at second cART initiation were independently associated
with a lower risk of failure (Table 3). The risk of virologic
failure declined consistently across calendar years, with the
most notable reductions in 2006 and 2008. The relative hazard
of virologic failure when second cART was initiated between
2008 and 2010, in comparison to starting between 1996 and
1998, was 0.40 (95% CI; 0.15, 1.00). Additional patient de-
mographic and clinical characteristics considered were not
associated with time to second cART virologic failure in
multivariable analyses, including sex, age, race, HIV trans-
mission risk group, history of AIDS-defining clinical condi-
tion, CD4 cell count at first cART initiation, HIV-1 RNA at
second cART initiation, time between end of first cART and
start of second cART, and anchor agent received.
Discussion
In this multicenter clinical cohort study of HIV patients in care
who were observed to switch from first to second cART, the
average time from therapy initiation to a second cART switch
was approximately 1.5 years and over one-third had HIV
RNA < 400 c/ml at therapy switch. Approximately one-quarter
of patients experienced virologic failure on their second cART by
1 and 2 years after starting their second cART depending on
whether their HIV RNA was above 400 c/ml or suppressed at
initiation, respectively. These results are comparable to recently
reported studies in modestly treatment-experienced patients
who received modern ritonavir-boosted PIs.20,21
The number of early second cART virologic failures ob-
served among patients who had a suppressed HIV RNA at the
time of switch from first to second cART regimens was sur-
prising. These findings emphasize caution when switching
cART in successfully treated patients. Optimistically we ob-
served notable reductions in the time to virologic failure of
second cART in more recent calendar years, with improve-
ments evident through 2008 to 2010, the latest calendar years
for which we had available data. Sample size restrictions
limited our ability to assess the contribution that increasing
use of newer ritonavir-boosted PIs, the NNRTI etravirine and
the INSTI raltegravir had on study results. However, this
finding is consistent with generally increasing HIV-1 RNA
suppression rates in more recent calendar years among
patients with varying exposure to cART in clinical care.22 We
hypothesized that the time between the end of first-line
therapy and the start of second-line therapy might be a mar-
ker of adherence to care, thereby influencing time to detect-
able HIV RNA on second-line therapy; however, in our
multivariable analysis this gap in treatment was not a sig-
nificant predictor of virologic failure.
The higher a patient’s CD4 cell count at second cART ini-
tiation the greater their probability was of achieving and/or
maintaining virologic suppression across time, even when
HIV RNA level at switch was included in the model. This
observation is consistent with prior work indicating that
higher CD4 cell counts at cART initiation are associated with
superior HIV-1 RNA outcomes,12 and clinical outcomes in-
cluding morbidity and mortality.23–25 Among patients with
detectable HIV-1 RNA at second cART initiation we observed
a shorter time to virologic failure in patients whose second
cART included a PI versus an NNRTI. The explanation for this
finding is not obvious. Most of the switches from NNRTI to PI
were among patients receiving older cART regimens, in-
cluding ritonavir-unboosted PIs, which for the most part were
less well tolerated and more complex to adhere to. While these
patients met our definition of virologic failure, they may have
had virologic rebound for reasons of tolerability and adher-
ence, and therefore the simplicity of the NNRTI regimen or its
better tolerability may have contributed to this finding.
The three large cohorts used for this study are highly rep-
resentative of the HIV epidemic in the United States, with a
substantial proportion of patients of black race, women, and a
distribution of HIV risk factors. Although combined these
three cohorts include over 15,000 HIV-infected patients, fewer
individuals met our inclusion criteria than anticipated. In part
this may be due to the high virologic suppression rates among
patients initiating first cART,12,17 and in part to our inclusion
criteria, specially the requirement that patients switch anchor
agents.
Our results emphasize that the orderly treatment cascade
from first NNRTI to second ritonavir-boosted PI-based ther-
apy is only one of many scenarios in clinical practice. The
majority of patients did not follow this particular sequence
and reached approximately 50% only in more recent years.
Randomized trials of early treatment failure have been diffi-
cult to conduct in the developed world setting in part due to
the diversity of initial regimens, reasons for treatment failure
and challenges with therapy, and visit adherence in this
population. Our findings suggest that obtaining data on
specific sequencing strategies will also be difficult using ob-
servational cohort data and will likely require very large
collaborative cohorts, with any specific treatment sequence
representing only a minority of patients.
Our study benefits from the use of data from three large
clinical care sites with well-established HIV cohorts, com-
parable data collection methods, and extensive prior
Table 3. Characteristics Associated with






CD4 cell count at second cART
start (per 100 cell/mm3 increase)
0.82 (0.75, 0.89)
Calendar year of second cART start
1996–1998 1.
1999–2001 0.79 (0.32, 1.81)
2002–2004 0.88 (0.38 2.06)
2005–2007 0.61 (0.25, 1.45)
2008–2010 0.40 (0.15, 1.00)
aEstimates based on fitting a multivariable Cox proportional
hazards model including all characteristics listed and clinical site.
95% CI, 95% confidence interval; cART, combination antiretroviral
therapy.
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collaborative experience.26 Additionally, our results have di-
rect relevance to clinical care given the representativeness of
the cohorts. However, our study, as other observational an-
alyses, may be subject to residual confounding, including
confounding by indication and selection bias. For example, if
certain patients were differentially prescribed an NNRTI
versus a PI as first ART based on factors not collected in this
study our results may be either underestimating or over-
estimating the time to second ART virologic failure. Another
limitation we encountered was sample size, which hindered
our ability to conduct subgroup analyses and evaluate addi-
tional secondary outcomes. Moreover, a number of factors
that may have affected our results were not considered, in-
cluding presence of antiretroviral resistance.
In summary, we present some of the first evidence of sec-
ond cART virologic outcomes among HIV patients in clinical
care. Our findings suggest that although therapeutic out-
comes are improving, notable numbers of patients have vi-
rologic failure of their second cART in a relatively short period
of time after switching therapy, including patients who initi-
ate second cART with HIV-1 RNA levels below 400 c/ml. Our
results also indicate that work assessing reasons for first cART
discontinuation and second cART initiation is needed to in-
form optimal therapy sequencing, including evaluating the
relative contributions of tolerability/toxicity, adherence, and
resistance evolution. These analyses will require efforts from
large national and international cohort collaborations.
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